Total Payments
$19,509
2024 Payments
$674.31
Companies
66
Transactions
861
Medicare Patients
1,900
Medicare Billing
$205,342
Payment Breakdown by Category
Food & Beverage$19,266 (98.8%)
Education$237.55 (1.2%)
Gifts$4.79 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,266 | 854 | 98.8% |
| Education | $237.55 | 6 | 1.2% |
| Gift | $4.79 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $3,636 | 147 | $0 (2023) |
| ViiV Healthcare Company | $2,931 | 98 | $0 (2024) |
| ABBVIE INC. | $1,288 | 42 | $0 (2024) |
| Janssen Biotech, Inc. | $1,213 | 60 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,097 | 60 | $0 (2024) |
| EMD Serono, Inc. | $806.12 | 35 | $0 (2024) |
| PFIZER INC. | $539.73 | 32 | $0 (2021) |
| Novo Nordisk Inc | $495.04 | 24 | $0 (2024) |
| Theratechnologies Inc. | $483.73 | 21 | $0 (2024) |
| Lilly USA, LLC | $480.12 | 26 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $674.31 | 27 | ABBVIE INC. ($170.83) |
| 2023 | $3,629 | 158 | Gilead Sciences, Inc. ($694.07) |
| 2022 | $2,779 | 106 | ViiV Healthcare Company ($688.04) |
| 2021 | $2,465 | 115 | Gilead Sciences, Inc. ($554.93) |
| 2020 | $1,353 | 62 | Janssen Biotech, Inc. ($213.83) |
| 2019 | $3,095 | 145 | Gilead Sciences, Inc. ($739.82) |
| 2018 | $2,753 | 132 | Gilead Sciences, Inc. ($554.06) |
| 2017 | $2,761 | 116 | AbbVie, Inc. ($485.26) |
All Payment Transactions
861 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: HIV | ||||||
| 04/04/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $27.10 | General |
| Category: HIV | ||||||
| 03/29/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: VACCINE | ||||||
| 03/28/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: PSYCHIATRY | ||||||
| 03/28/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Biological | ||||||
| 03/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Gastroenterology | ||||||
| 03/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: HIV | ||||||
| 03/13/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $29.49 | General |
| Category: PSYCHIATRY | ||||||
| 03/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Obesity | ||||||
| 03/12/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: HIV | ||||||
| 03/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: NEUROSCIENCE | ||||||
| 03/02/2024 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: HIV | ||||||
| 02/20/2024 | Pacira Pharmaceuticals Incorporated | Exparel (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Pain Management | ||||||
| 02/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.22 | General |
| Category: HIV | ||||||
| 02/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Obesity | ||||||
| 02/12/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Insomnia | ||||||
| 02/08/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Inflammation | ||||||
| 02/06/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.08 | General |
| 02/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.31 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $29.75 | General |
| Category: PSYCHIATRY | ||||||
| 01/25/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Respiratory | ||||||
| 01/23/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $34.62 | General |
| Category: NEUROSCIENCE | ||||||
| 01/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.30 | General |
| Category: NEUROSCIENCE | ||||||
| 01/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 505 | 660 | $180,100 | $59,628 |
| 2022 | 7 | 502 | 645 | $172,950 | $58,305 |
| 2021 | 6 | 463 | 582 | $152,350 | $50,420 |
| 2020 | 9 | 430 | 536 | $133,450 | $36,990 |
Total Patients
1,900
Total Services
2,423
Medicare Billing
$205,342
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 156 | 156 | $39,000 | $23,274 | 59.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 101 | 163 | $57,050 | $16,923 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 127 | 218 | $65,400 | $16,050 | 24.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 43 | 43 | $4,300 | $1,509 | 35.1% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 47 | 47 | $9,400 | $1,491 | 15.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 31 | 33 | $4,950 | $381.64 | 7.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 142 | 142 | $35,500 | $21,440 | 60.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 106 | 191 | $66,850 | $19,185 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 88 | 144 | $43,200 | $11,214 | 26.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 11 | 11 | $3,850 | $2,132 | 55.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 60 | 60 | $6,000 | $2,074 | 34.6% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2022 | 60 | 60 | $12,000 | $1,798 | 15.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 35 | 37 | $5,550 | $461.34 | 8.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 137 | 137 | $34,250 | $21,473 | 62.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 88 | 159 | $55,650 | $15,860 | 28.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 86 | 130 | $39,000 | $9,860 | 25.3% |
| 90756 | Vaccine for influenza derived from cell cultures for injection into muscle, quadrivalent, antibiotic free, 0.5ml dosage | Office | 2021 | 57 | 57 | $11,400 | $1,589 | 13.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 56 | 56 | $5,600 | $1,119 | 20.0% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 39 | 43 | $6,450 | $518.40 | 8.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 106 | 106 | $26,500 | $14,270 | 53.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 122 | $42,700 | $9,410 | 22.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 92 | 147 | $44,100 | $8,897 | 20.2% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2020 | 11 | 11 | $2,200 | $1,303 | 59.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 50 | 50 | $5,000 | $968.00 | 19.4% |
| 90688 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 50 | 50 | $3,750 | $958.50 | 25.6% |
About Dr. Stephen Dillon, MD
Dr. Stephen Dillon, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609855394.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Dillon, MD has received a total of $19,509 in payments from pharmaceutical and medical device companies, with $674.31 received in 2024. These payments were reported across 861 transactions from 66 companies. The most common payment nature is "Food and Beverage" ($19,266).
As a Medicare-enrolled provider, Dillon has provided services to 1,900 Medicare beneficiaries, totaling 2,423 services with total Medicare billing of $205,342. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location New York, NY
- Active Since 01/11/2006
- Last Updated 12/04/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1609855394
Products in Payments
- DOVATO (Drug) $1,113
- APRETUDE (Biological) $900.92
- SYMTUZA (Drug) $771.45
- TRIUMEQ (Drug) $510.72
- Androgel (Drug) $505.10
- SEROSTIM (Biological) $469.39
- XIFAXAN (Drug) $433.34
- Symtuza (Drug) $414.09
- EGRIFTA (Drug) $381.19
- REXULTI (Drug) $362.10
- VRAYLAR (Drug) $349.61
- ISENTRESS (Drug) $326.99
- Vascepa (Drug) $296.20
- MYRBETRIQ (Drug) $280.62
- UBRELVY (Drug) $258.25
- Biktarvy (Drug) $244.78
- PREZCOBIX (Drug) $243.78
- TRINTELLIX (Drug) $239.10
- JULUCA (Drug) $238.41
- TRULICITY (Drug) $228.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M